Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
EQL Pharma AB ( (SE:EQL) ) just unveiled an update.
EQL Pharma AB has signed a licensing agreement with Goodlife Specialty BV to distribute its key product, Memprex©, in the BeNeLux region, which includes Belgium, the Netherlands, and Luxembourg. Memprex©, a prophylactic treatment for recurring urinary tract infections, offers a non-antibiotic alternative that reduces the risk of developing antibiotic-resistant bacteria. This agreement marks a significant expansion for EQL Pharma into a new market of approximately 30.5 million people, potentially increasing its market presence and revenue streams.
More about EQL Pharma AB
EQL Pharma AB specializes in developing and selling generic drugs that are medically equivalent to original drugs, focusing on niche generics with limited competition. The company operates mainly in the Nordic and European markets, emphasizing prescription drugs and hospital products. EQL Pharma AB is based in Lund and is listed on the Nasdaq Stockholm stock market.
Average Trading Volume: 16,923
Current Market Cap: SEK2.67B
For a thorough assessment of EQL stock, go to TipRanks’ Stock Analysis page.